NCT07385417 Electroporation Treatment for Early AF Management in Heart Failure With Preserved Ejection Fraction (HFpEF) Pilot Study

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2023-04-12 with a primary completion date of 2026-04-12.

Brief Summary

The proposed pilot study is a prospective, randomized, single-center feasibility study, enrolling 200 patients with symptomatic paroxysmal AF. Per protocol, 100 patients will undergo a FARAPULSE electroporation PVI and 100 patients will receive standard AF medical treatment. Prior enrollment, all patients will be informed on the risk and benefits of the PVI procedure as well as the medical treatment. In addition, particular information on the rationale of the study, including a detailed risk/benefit analysis, will be provided to all patients.

Eligibility Criteria

Inclusion Criteria: 1. Seeking emergency (E) treatment including emergency room (ER) presentation 2. Paroxysmal AF diagnosed according to current ESC guidelines 3. Diagnosis of HFpEF according to ESC guidelines 2021 (clinical symptoms, EF\>50%, objective evidence of functional abnormality: LV diastolic dysfunction, NT-proBNP (non acute setting): sinus rhythm: 125pg/ml or AF: 365pg/ml, vs. acute HF: \>450 pg/ml if aged \<55 years, \>900 pg/ml if aged between 55 and 75 years and \>1800 pg/ml if \>75ys. 4. Age between 18 and 80 years 5. Left atrial size, LA \< 55mm 6. Left ventricular ejection fraction, EF \>50% 7. Patients able to provide informed consent and willing to comply with all pre-, post- and follow up requirements as per study protocol - Exclusion Criteria: 1. Currently participating in an interventional (drug, device, biologic, etc.) clinical trial 2. Any disease that limits life expectancy to less than one year 3. Contraindications for PVI 4. Contraindication for AAD therapy 5. Active systemic infection 6. Thrombocytosis, thrombocytopenia 7. Known pre-existing hemi-diaphragmatic paralysis 8. Any untreated or uncontrolled hyperthyroidism or hypothyroidism 9. Reduced immune function or otherwise at high risk for infection per physician discretion 10. Active malignancy or history of chemotherapy or radiation treatment 11. Prior left atrial ablation or surgical procedure (including left atrial appendage closures) 12. Any cardiac surgery, myocardial infarction, PCI/PTCA or coronary artery stenting which occurred within the 3 months before the eligibility assessment 13. Instable angina pectoris 14. Primary pulmonary hypertension 15. Any condition contraindicating chronic anticoagulation 16. Any cerebral ischemic event (strokes or TIAs) which occurred within the 3 months before the consent date 17. Presence of any cardiac prosthetic valves 18. Left atrial diameter \> 55 mm (anteroposterior) by TTE 19. Presence of any pulmonary vein stents 20. Presence of any pre-existing pulmonary vein stenosis (identified by CT or MRI and defined as at least 70% reduction of the PV diameter) 21. Endocarditis, pericarditis or pericardial effusion 22. Pregnant or breastfeeding women or women of childbearing potential not on adequate birth control. 23. Substance abuse 24. Unwilling to follow the study protocol and to attend follow-up visits \-

Contact & Investigator

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.